US 12,187,802 B2
IL3Ralpha antibodies and uses thereof
Ivan Bergstein, New York, NY (US)
Assigned to Stemline Therapeutics, Inc., New York, NY (US)
Filed by STEMLINE THERAPEUTICS, INC., New York, NY (US)
Filed on Dec. 23, 2020, as Appl. No. 17/132,726.
Application 17/132,726 is a continuation of application No. 16/393,863, filed on Apr. 24, 2019, granted, now 10,906,979.
Application 16/393,863 is a continuation of application No. 15/834,211, filed on Dec. 7, 2017, granted, now 10,316,098, issued on Jun. 11, 2019.
Application 15/834,211 is a continuation of application No. 15/342,668, filed on Nov. 3, 2016, granted, now 9,873,743, issued on Jan. 23, 2018.
Application 15/342,668 is a continuation of application No. 14/632,178, filed on Feb. 26, 2015, granted, now 9,518,119, issued on Dec. 13, 2016.
Application 14/632,178 is a continuation of application No. 13/439,453, filed on Apr. 4, 2012, granted, now 8,992,910, issued on Mar. 31, 2015.
Application 13/439,453 is a continuation of application No. 12/082,940, filed on Apr. 14, 2008, granted, now 8,163,279, issued on Apr. 24, 2012.
Claims priority of provisional application 60/923,499, filed on Apr. 13, 2007.
Prior Publication US 2021/0355226 A1, Nov. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 16/18 (2006.01); C12N 5/16 (2006.01); C12N 9/10 (2006.01); C12N 15/86 (2006.01)
CPC C07K 16/2866 (2013.01) [C12N 9/1048 (2013.01); C12N 9/1077 (2013.01); C12N 15/86 (2013.01); C12Y 204/02036 (2013.01); A61K 39/00 (2013.01); C07K 16/18 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/55 (2013.01); C12N 5/163 (2013.01)] 10 Claims
 
1. An anti-CD123 single chain fragment variable (scFv) encoded by a nucleic acid comprising nucleotide sequences that encode the complementarity determining regions (CDRs) of a variable heavy (VH) domain and a variable light (VL) domain, wherein the VH and VL domains bind the alpha subunit of the interleukin-3 receptor (IL3Rα), and wherein the CDRs comprise the VH domain CDR1 of SEQ ID NO: 3, the VH domain CDR2 of SEQ ID NO: 4, the VH domain CDR3 of SEQ ID NO: 5, the VL domain CDR1 of SEQ ID NO: 8, the VL domain CDR2 of SEQ ID NO: 9, and the VL domain CDR3 of SEQ ID NO: 10.